Last reviewed · How we verify
NCT04456348: ACCURATE-2
Association Between Gait Assessed by Intelligent System and Cognitive Function in Silent Cerebrovascular Disease
trial testing there is no intervention in Silent Stroke in 1,600 participants. Status unknown.
31 October 2021
Quick facts
| Lead sponsor | Shanghai Zhongshan Hospital |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 1,600 |
| Start date | 1 July 2020 |
| Primary completion | 31 October 2021 |
| Estimated completion | 31 December 2021 |
Drugs / interventions tested
- there is no intervention — full drug profile →
Conditions studied
- Silent Stroke — all drugs for Silent Stroke →
Sponsor
Shanghai Zhongshan Hospital
Who can join
Adults 60 to 85, any sex, with Silent Stroke. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study is a multi-center prospective cohort study. We will continuously recruit subjects with silent cerebrovascular disease aged 60 to 85 years from Shanghai and Guizhou. Data including demographic characteristics, medical history, other concomitant diseases, neurological function assessments, laboratory examinations, imaging examinations, and other clinical data and health economics survey responses will be collected from all subjects. At baseline, all subjects will undergo gait assessment using the intelligent system and cognitive function scale assessment by clinicians. According to the intelligent gait results, the subjects will be divided into normal and abnormal gait groups. All subjects will be observed naturally for 1 year, and all medical behaviors will be recorded. All subjects will be interviewed by telephone for the occurrence of vascular events and changes in medical behaviors at half a year after enrollment and followed up at 1 year after enrollment, including gait evaluation using the intelligent system and cognitive function scale evaluation by clinicians. During the follow-up period, patients can visit the hospital for follow-up at any time when their condition changes.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Association between gait features assessed by artificial intelligent system and cognitive function decline in patients with silent cerebrovascular disease: study protocol of a multicenter prospective cohort study (ACCURATE-2).
Tang YM, Fei BN, Li X, Zhao J, et al · · 2022 · cited 2× · PMID 35773649 · DOI 10.1186/s12883-022-02767-2
Verify or expand the search:
- PubMed search for NCT04456348
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of there is no intervention
Trials testing the same drug.
- NCT07396467 — Clinical Outcomes and Immunotherapy in Lung Cancer With Pulmonary Fibrosis · active not recruiting
- NCT05912413 — Predicton of Sepsis Recovery Performance Subtypes Pilot Study · recruiting
- NCT05564923 — CARG, VES13, G8 Scales in Predicting Drug Toxicity in Patients Receiving Nivolumab · unknown
- NCT07021326 — Phase Angle and TyG Index as Markers of Glycaemic Control, Adiposity and Cardiovascular Risk in T1D Adolescents · completed
- NCT04212143 — Central Blood Pressure and Pulse Wave Velocity in Kidney Transplant Recipients · active not recruiting
Other recruiting trials for Silent Stroke
Currently open trials in the same condition.
- NCT06545786 — Intraoperative Diagnosis of Neurocognitive Complications Via Electroencephalographic Analysis · recruiting
- NCT04808778 — Stroke Prevention in Young Adults With Sickle Cell Anemia · active not recruiting
- NCT04449523 — Incidence of Silent Atrial Fibrillation in Patients With Clinically Silent Brain Ischemic Lesions · recruiting
- NCT05685069 — Prevalence of Attributable Etiology and Modifiable Stroke Risk Factors in Patients With Covert Brain Infarctions · recruiting
Other Shanghai Zhongshan Hospital trials
Trials by the same sponsor.
- NCT07353476 — Radiotherapy Plus Anti-PD-1 Versus Anti-PD-1 Alone in ypTanyN⁺M0 NSCLC · Phase 2 · not yet recruiting
- NCT07508956 — Feasibility of Circulating Tumor DNA Based Minimal Residual Disease-Guided Adjuvant Therapy in Locally Advanced Gastric · Phase 3 · not yet recruiting
- NCT07535632 — SBRT Followed by PD-1 Inhibitor, Bevacizumab and TAS-102 as Third-Line Therapy for Recurrent/Metastatic Colorectal Cance · Phase 2 · not yet recruiting
- NCT07531368 — BBAP With CS Mapping Guidance · NA · not yet recruiting
- NCT07501104 — Neoadjuvant Pucotenlimab Combined With Lenvatinib and Temozolomide in Resectable Stage IIB/III Acral Melanoma · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04456348 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Shanghai Zhongshan Hospital
- Last refreshed: 2 July 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04456348.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing